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COVID-19, cell envelope protease
Immune modulation
Substrate specificityThe Streptococcal C5a peptidase (ScpA) specifically inactivates the human complement factor hC5a, a
potent anaphylatoxin recently identified as a therapeutic target for treatment of COVID-19 infections.
Biologics used to modulate hC5a are predominantly monoclonal antibodies. Here we present data to sup-
port an alternative therapeutic approach based on the specific inactivation of hC5a by ScpA in studies
using recombinant hC5a (rhC5a). Initial characterization of ScpA confirmed activity in human serum
and against rhC5a desArg (rhC5adR), the predominant hC5a form in blood. A new FRET based enzyme
assay showed that ScpA cleaved rhC5a at near physiological concentrations (Km 185 nM). Surface
Plasmon Resonance (SPR) and Isothermal Titration Calorimetry (ITC) studies established a high affinity
ScpA-rhC5a interaction (KD 34 nM, K
ITC
D 30.8 nM). SPR analyses also showed that substrate binding is
dominated (88% of DGbind) by interactions with the bulky N-ter cleavage product (PN, ’core’ residues
1–67) with interactions involving the C-ter R74 contributing most of the remaining DGbind.
Furthermore, reduced binding affinity following mutation of a subset of positively charged Arginine resi-
dues of PN and in the presence of higher salt concentrations, highlighted the importance of electrostatic
interactions. These data provide the first in-depth study of the ScpA-C5a interaction and indicate that
ScpA’s ability to efficiently cleave physiological concentrations of C5a is driven by electrostatic interac-
tions between an exosite on the enzyme and the ‘core’ of C5a. The results and methods described herein
will facilitate engineering of ScpA to enhance its potential as a therapeutic for excessive immune
response to infectious disease.
 2021 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and
Structural Biotechnology. This is an open access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).1. Introduction
The role of the complement factor C5a in inflammatory diseases
has come into sharp focus in recent months, with data supporting a
role for C5a-C5aR in the progression of COVID-19 disease [1]. The
therapeutic value of targeting C5a as an intervention in COVID-
19 infection is demonstrated by multiple ongoing Phase III clinical
studies using anti-C5a monoclonal antibodies (MAbs) [2–5]. Com-
plement therapeutics have garnered increasing attention as strate-gies for treatments of inflammatory diseases [6,7]. Proteases are
also being explored for their potential to modulate the comple-
ment response in the disease process. Examples include an engi-
neered human MTSP1 protease targeting C3 as a treatment of
age-related macular degeneration (AMD) [8] and the use of ScpA,
a bacterial protease specific for C5a, as an intervention in sepsis [9].
The ScpA enzyme is one of two multi-domain cell envelope pro-
teases (CEPs) produced by the Gram-positive bacterium Streptococ-
cus pyogenes. The second enzyme is the IL-8 cleaving peptidase
ScpC (also known as SpyCEP). Unlike degradative subtilases, ScpA
and ScpC have high substrate specificity. ScpC has been shown to
selectively cleave and inactivate CXC chemokines that possess
the ELR motif [10], thus targeting a structurally conserved
carboxyl-terminal (C-ter) helix in chemokines which stimulate
neutrophil migration [11,12]. ScpA is a more selective enzyme
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The better characterized substrate for ScpA is C5a, a 74 amino-acid
pro-inflammatory product of complement activation with a myriad
of significant biological functions [14,15]. ScpA inactivation of
human C5a (hC5a) results from a single proteolytic event between
residues H67 and K68 [13], releasing the 7 C-terminal (C-ter) resi-
dues of the chemotaxin associated with receptor activation [16].
The amino-terminal (N-ter) cleavage product (PN, residues 1–67,
referred to as the ‘core’ residues or ‘hC5acore’) has greatly reduced
PMN chemotactic and stimulatory activity as compared to the
full-length C5a peptide [17]. From the perspective of bacterial vir-
ulence, the action of these two CEPs modulate the host immune
response and promote bacterial persistence.
The current study examines factors contributing to ScpA’s
specificity for hC5a, and therefore how it exerts an immune-
modulatory effect. Early characterizations of the peptidase showed
that ScpA did not cleave native forms of a variety of proteins (C5,
human serum albumin, ovalbumin, soybean trypsin inhibitor, car-
bonic anhydrase, a-lactalbumin, myosin, and cytochrome), but
demonstrated endoproteolytic activity against hC5a [14,15]. More
recently, ScpA has also been shown to be capable of cleaving C3a,
the structurally related complement derived anaphylotoxin [14].
In addition, ScpA was observed to discriminate between C5a mole-
cules from different species, inactivating bovine C5a but not the
mouse or rat proteins [18].
While the specificity of ScpA has not been exhaustively tested, it
has historically been considered a highly discriminating enzyme.
The specificity of ScpA has been examined in both enzyme kinetic
and substrate binding. To date, enzyme kinetic studies on ScpA
have relied on use of small peptide mimics or large chimeric fusion
proteins as substrate analogues. Studies with a 16 amino-acid pep-
tide representing the C-ter of hC5a, reported kcat and Km values of
1.1 s1 and 360 lM respectively for ScpA [19]. Additional analysis
with a peptide substrate lacking the 7 C-ter tail residues decreased
kcat/Km more than 200 fold, demonstrating the importance of prime
side interactions in determining substrate interactions. Several
studies expanded the substrate to include the entire C5a molecule.
Stafslien and Cleary employed a Glutathione S transferase-C5a-
green fluorescent protein tripartite fusion as a substrate and
reported specific activity for ScpA, but not other kinetic parameters
[20]. However, their study did confirm the identity of the catalytic
residues (D130, H193, and S512), and demonstrated that peptidase
activity decreased with increasing (20–200 mM) NaCl concentra-
tion [20]. In addition, Terao and co-workers examined interaction
between active ScpA and the full-length human C5a in Surface
Plasmon Resonance (SPR) studies which indicated that the pepti-
dase binds hC5a with very low affinity (KD 7.25 mM) [21].
When considering activity of an enzyme such as a protease, it is
important to relate the observations on Km to the physiological
concentration of its substrate. Data from clinical samples under
conditions where C5a is expected to be elevated indicate that
physiological levels of C5a are in the low nM range (10–30 nM)
for a variety of clinical indications including intra-abdominal infec-
tions [22], sepsis [23] and COVID-19 infection [2,24]. Thus, the sub-
strate analogues used in previous studies do not adequately
account for interactions critical for examining the properties of
ScpA. Understanding of ScpA as a virulence factor and potential
therapeutic would benefit from an improved substrate for kinetic
analysis.
The structure of ScpA showed that it is a subtilisin-like protease
with a PA domain inserted within the catalytic domain and 3 tan-
demly arranged C-terminal fibronectin type III domains (Fn1-Fn3)
[44] . Based on proximity to the active site, the PA and Fn2 domains
were proposed to participate in substrate interactions in the active
site and at an exosite respectively. Furthermore, modelling of the
ScpA-hC5a complex indicated that the catalytic site is occluded2357and would be inaccessible to large, folded substrates. Therefore,
positioning of the scissile bond near the catalytic site required that
the hC5a residues in the C-ter a-helix (residues 65–74) adopt an
extended conformation. Interactions with the Fn2 domain were
predicted to make the largest contribution to substrate binding
affinity, involving a large surface area and 9 salt bridges with
hC5a residues between residue 1 and residue 64. These exosite
interactions between the hC5acore residues and the Fn2 domain
would compensate for the limited number of stabilizing interac-
tions in non-prime side of the active site. The model also proposed
that ionic interactions with 3 hC5a residues in the C-ter tail (K68,
D69 and R74) would be involved in substrate binding.
Here we present enzyme kinetic data, along with the surface
(SPR) and solution (Isothermal Titration Calorimetry) protein–pro-
tein interaction studies that probe the ScpA-hC5a interaction. The
results of these studies are the first to be consistent with physio-
logically relevant concentrations of C5a. These data thus provide
in-depth insight into the determinants of ScpA specificity, a critical
initial step in developing this enzyme into novel therapeutics for
immunomodulatory disorders involving C5a.2. Materials and methods
2.1. Preparation of recombinant proteins
The cloning of recombinant ScpA, residues 31–1032, has been
described previously [44], and was designed to closely mimic the
form of ScpA released from the surface of the Group A Streptococ-
cal cell by the action of SpeB, and which is reported to retain activ-
ity [25]. For the purposes of this work this protein is called ScpA.
The plasmid expressing ScpA (pGEX ScpA(31-1032)) was used as a
template to generate an active site serine to alanine (S512A) muta-
tion with the QuickChange II site directed mutagenesis kit (Strate-
gene, USA) for use in SPR studies. The proper folding of ScpAS512A
was confirmed crystallographically (Supplemental Information,
Table S2 and Fig. S4), and the coordinates and structure factors
deposited at the Protein Data Bank (PDB ID 7BJ3).
Recombinant human C5a peptides were produced as N-ter
hexa-histidine tagged (HT) fusion proteins using a protocol which
closely followed the method of Bubeck et al. [26]. Synthetic genes
for human C5a were inserted into the pProExHTb expression vector
(Invitrogen, UK). Unless otherwise stated point mutations were
generated using a QuickChange II site directed mutagenesis kit
(Strategene, USA) with specific primers, and using the pProEXHTb
construct for rhC5a as the template. The synthetic gene for rhC5a
with an additional C-ter C75 residue (rhC5aC75) was generated
using gblock technology (IDT Biotech). The rhC5acore was purified
from a treatment of rhC5a with ScpA. For competitive binding
experiments, TEV protease (Sigma Merck, U.S.A) was used to pro-
duce the His-tagless form of rhC5a (rhC5a-HT).
Additional details of recombinant protein production and
purification are provided in Supplemental Information.2.2. ScpA activity assays
The activity of recombinant ScpA against rhC5a, rhC5adR and
rhC5aC75-BODIPY was examined in cleavage assays containing
18 lM C5a peptide and 10 nM ScpA in PBS. The reactions were
incubated at 37 C for 15 min and analyzed by SDS-PAGE and
MS. Salt dependent activity assays were conducted in 30 mM
Hepes buffer with 10 mM, 150 mM and 1 M NaCl adjusted to pH
7 with KOH. 17 mM rhC5a was cleaved with 10 nM ScpA under each
buffering condition for 7 min at 37 C and assessed with SDS-PAGE.
ScpA activity was also demonstrated in human serum. Reac-
tions were in normal human serum (Merck, Germany) with
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37 C. The reactions were immediately passed through a Pro-
teoSpinTM protein depletion column (Norgen Biotek, Canada) and
rhC5a cleavage assessed with SDS-PAGE. These assays were con-
ducted at higher concentrations of rhC5a to facilitate visualization
of the digestion product anticipating dilution of rhC5a using the
ProteoSpinTM protein depletion column. Western blot analysis of
the samples used polyclonal rabbit anti-human C5a antibody
(MBS524143, MyBioSource, USA).
The rate of reaction of cleavage of C5a by ScpA was determined
in an assay using the self-quenched doubly BODIPY labelled His-
tagged rhC5aC75 as a substrate. Production of the substrate is
described in Supplemental Information. Enzyme kinetics assays
contained 16, 31, 62, 125, 250 or 500 nM of the labelled substrate
and 180 pM ScpA in 1 X PBS with 0.1% (v/v) Tween 20. The reac-
tions were performed at 25 C, and the evolution of fluorescence
monitored over 8000 s using a Berthold Tristar2S fluorescence
plate reader (Berthold Technologies, UK) with excitation at
485 nm and emission at 520 nm and a 2 s data acquisition time.
Experiments were performed in quadruplicate. Following correc-
tion for spontaneous hydrolysis of substrate the progress curves
were analysed using the DYNAFIT software package [27]. Progress
curves were fit with the minimal Van Slyke-Cullen mechanism [28]
to obtain steady state enzyme kinetic parameters (Km and kcat).2.3. Surface plasmon resonance studies
SPR data was obtained by measuring of the His-tagged C5a pep-
tides to ScpAS512A was measured at 25 C with a BIAcore X100 sys-
tem (GE Healthcare, UK) in Hepes buffer (10 mM Hepes-KOH pH
7.5, 150 mMNaCl, 0.005% (v/v) Tween 20, 50 lM EDTA). The exper-
iments were conducted in triplicate. Values of binding constants
reported on Table 1 represent the mean and standard deviation
from three experiments. Interactions with the human C5a peptides
(rhC5a, rhC5adR, rhC5acore and point mutations) were assessed
with an NTA sensor chip (GE Healthcare, UK) with approximately
30–40 response units (RU) of immobilized peptide ligand and a
flow rate of 30 lL/min. The binding to human C5a peptides was
measured over a range of ScpAS512A concentrations (32-fold)
divided equally over 6 experiments (i.e. 2-fold change in ScpAS512A
concentration between measurements). Association and dissocia-
tion phases were each monitored for 200 s. The highest ScpAS512A
concentrations were 90, 500, and 1000 nM for rhC5a, rhC5adR,
and rhC5acore binding respectively. The highest ScpAS512A concen-
tration was 90 nM for rhC5aK4A,K5A, rhC5aK12A,K14A, and rhC5aK49A,
360 nM for rhC5aR46A, and 720 nM for rhC5aR37A and rhC5aR40A.Table 1
Kinetic and thermodynamic parameters for ScpAS512A binding to C5a peptides.
ka  104 (M1s1)a kd 
rhC5a (150 mM NaCl) 13.1 ± 0.3
rhC5a (350 mM NaCl) 6.85 ± 0.95 4
rhC5a (550 mM NaCl) 3.92 ± 0.38
rhC5a (750 mM NaCl) 2.56 ± 0.28 6
rhC5a (950 mM NaCl) 1.953 ± 0.137 9
rhC5acore 3.52 ± 0.05
rhC5adR 6.17 ± 0.52 1
rhC5aK4A,K5A 18.0 ± 1.2 5
rhC5aK12A,K14A 15.8 ± 1.2 4
rhC5aR37A 8.12 ± 0.49 1
rhC5aR40A 8.80 ± 0.74 2
rhC5aR46A 11.1 ± 1.3 1
hC5aK49A 19.5 ± 1.0
a Reported as mean and standard deviation from 3 experiments.
b DDG = RTln[KD /KD (rhC5a, 150 mM NaCl)], R = 1.986 (cal mol1 K1), T = 298 K.
c Binding energy for rhC5a at 298 K , DGbind = -RTln[1/KD] = -10.2 kcal/mol.
2358Double referencing was used to remove the effects associated with
buffer changes. In addition, the signal associated with non-specific
ScpAS512A interactions with the chip surface was subtracted from
each sensorgram. The sensorgrams were fit in a global analysis
with the BIAevaluation 4.1 curve fitting software (GE Healthcare,
UK). The best fit (lowest chi2) was obtained using 1:1 Langmuir
model with a drifting baseline.
2.4. Competitive binding assay
The competition between ScpA binding to immobilized
rhC5acore and the His-tagless form of rhC5a in solution (rhC5acore(-
imm) and rhC5a-HT(sol) respectively in Scheme 1) was used to esti-
mate the ScpA-rhC5a equilibrium dissociation constant in solution
(KSolD ). The equilibrium SPR response (Req) was measured over a
range rhC5a-HT concentrations with fixed levels of immobilized
rhC5acore and ScpA concentrations. 40 RU of HT-rhC5acore was
immobilized on a NTA biosensor chip. Mixtures of ScpAS512A
(700 nM) and rhC5a-HT (0–2000 nM) were pre-incubated in SPR
running buffer (1 hr on ice) prior to injection over both flow cells
(30 mL/min for 180 sec). Req values obtained from these experi-
ments were analyzed according to the method reported by More-
lock et al. [29].
In brief, the Req in the competition assay measures ScpAS512A-
rhC5acore binding on the chip surface, which is dependent on the
concentration of free ScpAS512A in solution (i.e. [ScpA]Tot –
[ScpArhC5a-HT] (Eq. 1). Where [ScpA]Tot is the total concentration
of ScpAS512A, [ScpArhC5a-HT] is the concentration of the ScpAS512A-
rhC5a-HT complex in solution, KcoreD is the SPR derived constant for
ScpA-rhC5acore binding (Table 1), and Rmax and Rmin are the maxi-
mum and minimum Req responses in the competition assay.
[ScpArhC5a-HT] can be obtained from the quadratic solution of
the expression for KSolD (Eq. 2). Substitution of Eq. 2 into Eq. 1 allows
estimation of KSolD by fitting plots of [rhC5a-HT]Tot versus Req with
fixed values of [ScpA]Tot (700 nM), K
core
D (240 nM), and Rmin (0.0).
2.5. ITC determination of equilibrium dissociation constant (K ITCD )
Isothermal titration calorimetry (ITC) was used to measure
thermodynamic parameters for ScpAS512A-rhC5a binding in solu-
tion. Measurements were performed using an iTC200 calorimeter
(MicroCal, U.S.A.) equipped with a 200 lL sample cell (GE Health-
care). Purified protein samples were extensively dialysed against
50 mM Hepes-KOH buffer, pH 7.5 containing 150 mM NaCl. The
reference power was set to 4.5 lcal/sec and the instrument was
equilibrated to 25 C. ScpAS512A (18 lM) was placed in the sample103 (s1)a KD (nM)a DDG (kcal/mol)b
4.4 ± 0.3 34 ± 3 0c
.31 ± 0.28 63.5 ± 7.5 0.4
5.4 ± 0.5 140 ± 20 0.8
.51 ± 0.43 256 ± 30 1.2
.10 ± 0.78 466 ± 30 1.5
8.5 ± 0.3 240 ± 10 1.2
1.8 ± 1.0 191 ± 9 1.0
.83 ± 0.37 32.5 ± 3.0 0.0
.05 ± 0.30 25.6 ± 0.3 0.2
7.6 ± 0.1 217 ± 11 1.1
0.5 ± 1.4 234 ± 20 1.1
7.8 ± 0.7 162 ± 21 0.9
5.0 ± 0.7 26 ± 2 0.2
Scheme 1. The scheme shows the equilibria involved in the competition between ScpA binding to full length rhC5a in solution vs rhC5acore immobilized to the chip surface
(rhC5a-HT(sol) and rhC5acore(imm) respectively). The equilibrium dissociation constant for ScpA-rhC5a-HT binding in solution (K
Sol
D ) is obtained by fitting of equilibrium
response units (Req) measured with varying concentrations of rhC5a-HT(sol) using Equation 1. [ScpArhC5a-HT] in Eq. 1 is obtained from the quadratic solution for the
expression for KSolD (Eq. 2). K
core
D is the equilibrium dissociation constant for ScpA binding to immobilized rhC5acore obtained from SPR experiments (Table 1).
Fig. 1. ScpA enzyme kinetics and activity against rhC5adR. (a) SDS-PAGE analysis of
recombinant rhC5a and rhC5adR cleaved with ScpA. Lanes with ‘+’ and ‘-’ indicate
samples with and without ScpA, respectively. rhC5a and rhC5adR treated with ScpA
produced fragments of similar size (indicated with an arrow marked ‘core’).
Molecular weight ladders are shown on the left side of the gels in Fig. 1a and 1b in
kDa. Mass spectrometry of cleaved rhC5a and rhC5adR show that the observed mass
of the products (10886.1 Da and 10885.6 Da, respectively) are consistent with
rhC5acore (calculated mass 10886.2 Da.). Observed and calculated (parenthesis)
masses are reported for rhC5a and rhC5adR. (b) The activity of ScpA was examined
in human serum. The Coomassie stained polyacrylamide gel and Western blot
analysis shows that ScpA (36 nM) cleaves rhC5a (39 mM) in human serum. The
arrow indicates the expected position for the ‘core’ (PN) product of ScpA cleavage of
C5a. (c) Progress curves for ScpA cleavage of rhC5aC75-BODIPY. Data are plotted
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interval between the injections and stirring (1000 rpm). Titration
data were collected in triplicate and analysed with the ORIGIN
software package (MicroCal, U.S.A.). The peaks areas were inte-
grated and corrected for the heat of rhC5a dilution. Plots of kcal/-
mol of injectant versus molar ratio were analyzed with the ‘one
set of sites’ model to obtain values for the association binding con-
stant (KA), stoichiometry (N), and the enthalpy of binding (DHbind),
entropy of binding (DSbind) were determined. The reported equilib-
rium dissociation constant (K ITCD ) was derived from KA.
2.6. Mass spectrometry analysis of recombinant rhC5a and rhC5aC75
proteins
Intact mass analysis of rhC5a and rhC5aC75 proteins were per-
formed in-house on a Bruker UltrafleXtreme instrument (Bruker
Daltonik GmbH, Germany), using Compass 1.4 software unless
otherwise stated. The sample preparation followed the dry droplet,
two-layer method as per [30]. Protein samples were diluted with
0.1% TFA to final concentrations of 50 mg/mL and 15 mg/mL for
rhC5a and rhC5aC75 samples, respectively. Analyte solutions con-
sist of a 1:1 mixture of the diluted protein samples and a saturated
solution of sinapinic acid (Bruker Daltonik GmbH, Germany) in 30%
acetonitrile, 0.1% TFA (v/v). A saturated matrix solution of sinapinic
acid in ethanol was layered onto a stainless-steel target plate and
allowed to air dry. 0.5 mL of the analyte solution was applied as
the second layer to the target and allowed to dry. Spectra were
recorded in the positive linear mode and externally calibrated
using Protein Calibration Standard I (Bruker Daltonik GmbH, Ger-
many). Germany). Masses of rhC5a and its mutants were calculated
from amino acid sequences with the PROTPARAM tool on the
ExPASy server [31]. Calculated masses include an additional
70 Da to account for disulfide bond linkages and the addition of
b-mercaptoethanol to C27 in the refolding process.with curves from global fitting of 6 progress curves to the Van Slyke-Cullen model.
Values for kcat and Km are reported as the mean and standard deviation of the mean
from 3 experiments. Data shown in the plot are from 3 experiments. A key to
substrate concentrations is provided on the right-hand side of the graph.3. Results
3.1. ScpA is active against both major forms of C5a found in blood
C5a in human blood is rapidly cleaved by carboxypeptidases to
the C5a des Arg form which lacks the C-ter R74 residue [32]. While
C5a des Arg is reported to have reduced potency as compared to
C5a, it still retains biological activity [34,34]. The ScpA enzyme (de-
fined as residues 32–1032 of the wild-type enzyme) cleaved
recombinant forms of human C5a and C5a des Arg (rhC5a and
rhC5adR, respectively) in agreement with data on C5a proteins iso-
lated from human serum [15]. A decrease in molecular weight for
both forms of C5a was observed in the presence of ScpA (Fig. 1a).
The mass of larger digestion product was confirmed to be the core
portion of C5a (residues 1–67, rhC5acore) (Fig. 1a). These analyses2359demonstrated that the same N-ter product (PN) was released by
ScpA from both rhC5a and rhC5adR. Thus, ScpA is capable of inacti-
vating both major forms of C5a by targeting the same scissile bond
between residues H67 and K68. Furthermore, the C5a-ase activity
of the ScpA was assessed in a more biologically relevant solution.
These assays showed that ScpA readily cleaved rhC5a to near com-
pletion in human serum (Fig. 1b), supporting the ability of the
recombinant enzyme to function as expected in biological fluids,
and demonstrating a potential for the development of ScpA as a
therapeutic enzyme.
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respectively
Characterization of the kinetics of C5a cleavage by ScpA utilized
fluorescent substrate based on the full length C5a with two self-
quenching BODIPY moieties on the core and tail portion of the
molecule (Supplemental Fig. S1). The labelling chemistry target
the free thiols of the naturally occurring C27 residue and the intro-
duced C-terminal C75 residue (rhC5aC75). In preliminary studies,
the doubly labelled rhC5aC75-BODIPY form of C5a was found to
be readily cleaved by ScpA, producing fragments of the expected
mass for the labelled PN and tail portions (PC) of the substrate (Sup-
plemental Fig. S1).
Kinetic parameters were determined using a full range of sub-
strate concentrations under conditions where the enzyme concen-
tration was much less than the concentration of the substrate
(Fig. 1c). Progress curves were fit with the minimal Van Slyke-
Cullen mechanism to obtain steady state enzyme kinetic parame-
ters giving a Km and kcat of 185 ± 6 nM and 0.886 ± 0.019 sec-1,
respectively. The kcat/Km of 4.79 X 106 M1s1 is well below that
expected for a diffusion limited enzymatic reaction [35]. In con-
trast to other substrates used to measure ScpA activity, the
observed Km for rhC5aC75-BODIPY is consistent with the nM con-
centrations of C5a in vivo and thus a very sensitive probe to study
the specificity determinants of ScpA.
3.3. ScpA binds to rhC5a with nM affinity
To explore how ScpA recognizes and binds to its substrate C5a
in greater detail, a series of protein–protein interaction studies
was performed. To circumvent potential complexities expected
when measuring substrate binding to an active enzyme, surface
plasmon resonance (SPR) studies utilized the S512A active site
mutant of ScpA (ScpAS512A) and recombinant His-tagged C5a pep-
tides. The sensorgrams observed for ScpAS512A binding to immobi-Fig. 2. SPR and ITC characterization of ScpAS512A-rhC5a binding. (a) Representative
SPR sensorgrams of ScpAS512A binding to immobilized full length rhC5a. Observed
data (black lines) are shown with curves obtained from global fitting of data with a
1:1 Langmuir model for binding (red lines). The mean KD value obtained from 3
experiments is reported. (b) Thermodynamic parameters obtained from calorimet-
ric titration of ScpAS512A with rhC5a. Mean and the standard deviation of the mean
are reported for 4 experiments. Panel c shows ITC data from a single measurement.
Peaks from the titration data were integrated and corrected for the heat of dilution
of rhC5a. The enthalpy per mole of rhC5a injected was plotted against the
ScpAS512A:rhC5a molar ratio and fit with the ‘one set of sites’ model. (For
interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
2360lized rhC5a were well accounted for with global fitting of the data
using a 1:1 Langmuir binding model (Fig. 2a). All binding constants
are reported on Table 1
For rhC5a binding, the average association (ka) and dissociation
rates (kd) were 13.1 X 104 M1s1 and 4.4 X 10-3 s1 respectively.
The equilibrium dissociation constant (KD) derived from these
kinetic parameters was in the low nM range (34 nM) indicating
that ScpA has a high affinity for rhC5a. The magnitude of the ka
is at the theoretical boundary between protein–protein association
rates limited by diffusion versus those limited by conformational
changes [36]. Faster rates implicate the involvement of comple-
mentary long-range electrostatic interactions, while slower rates
are expected to result from larger structural rearrangements such
as changes in domain orientation.
The SPR data are supported by additional ITC studies (Fig. 2b
and c) that more accurately reflect binding in solution. The analysis
confirms that the substrate binds to ScpA at a single site with high
affinity (K ITCD = 30.8 nM). The ITC measurements also indicated that
the binding of the substrate is an enthalpically driven process with
a DH of 9.4 kcal/mol and DS of 2.3 cal/mol/deg. This is consistent
with the published model which highlighted 22 hydrogen bonds,
and 15 salt-bridges between the substrate and enzyme [44].
Importantly, the KD values reported here indicate that the enzyme
is capable of binding C5a at physiological concentrations and is in
good agreement with the Km measured with the doubly labelled
C5a substrate (Section 3.2). The observed values indicate a consid-
erably tighter binding than has previously been reported. The
interaction between wild type ScpA and the full-length substrate
was examined by others in SPR studies which indicated that the
peptidase binds rhC5a with very low affinity (KD 7.25 mM) [21].
The discrepancy may be related to differences in the SPR experi-
mental details, most notably the use of the active enzyme which
complicates the interpretation of binding data. Taken together
these data indicate a high affinity interaction between ScpA and
its substrate C5a, and that the described enzyme kinetic and SPR
methods are sensitive tools for detailed characterization of ScpA
substrate interactions.3.4. Binding studies indicate exosite binding interaction between ScpA
and C5a
Binding of ScpA to the larger core portion of C5a (rhC5acore)
was also measured by SPR. rhC5acore represents the larger N-
terminal product (PN) of ScpA inactivation. As with the full length
rhC5a, the binding curves are well accounted for with a 1:1 Lang-
muir binding model supporting a single binding site for the
rhC5acore. Fig. 3a shows the global fitting of the sensorgrams
obtained for binding of rhC5acore. The KD for rhC5acore binding
was observed to be in the nM range (240 nM, Table 1), approxi-
mately eight-fold greater than for the full length rhC5a
(Section 3.3).
Though it is likely that rhC5acore and rhC5a bind to the same
region on ScpA, it is possible that two distinct sites exist for bind-
ing of these entities. This was examined in an SPR based competi-
tion binding study using a tag-less form rhC5a (rhC5a-HT). Fig. 3b
shows that binding of ScpA to immobilized rhC5acore was reduced
with increasing concentrations of free rhC5a-HT in solution. This
indicates that the full length and core portion of C5a compete for
a single binding site on ScpA. Fitting of the competitive binding
curve to Eq. 1 provides an estimate for solution binding affinity
ðKSolD Þ. A KSolD of 11.1 nM again supports a high affinity interaction
between ScpA and C5a in solution.
Additional insight into how ScpA binds C5a was gained by com-
paring the binding energies for rhC5a and rhC5acore. The difference
in binding energy (DDG, Table 1) between rhC5a and rhC5acore
Fig. 3. ScpAS512A binding to rhC5acore, rhC5adR and competition binding assay.
Panels (a) and (c) show representative sensorgrams of ScpAS512A binding to
rhC5acore and rhC5adR respectively. Observed data (black lines) are plotted with
curves obtained from global fitting of data with a 1:1 Langmuir model for binding
(red lines). Mean KD values obtained from 3 experiments are reported. (b) Req values
from competition binding assay measuring ScpAS512A binding to immobilized
rhC5acore in the presence of increasing concentrations of rhC5a in solution
(rhC5a-HT). The concentration of rhC5a-HT is plotted on a log scale. Fitting of the
data to Eq. 1 (solid line) provides the equilibrium dissociation constant for
ScpA-rhC5a-HT in solution (K
Sol
D ). The value for K
Sol
D is reported with the standard
error for the fitting. (For interpretation of the references to colour in this figure
legend, the reader is referred to the web version of this article.)
Fig. 4. SPR analysis of the salt dependence of ScpAS512A-rhC5a binding and activity.
Panels (a) through (d) show representative sensorgrams of ScpAS512A binding to
rhC5a in the presence of 350, 550, 750 and 950 mM NaCl respectively. Observed
data (black lines) are plotted with curves obtained from global fitting of data with a
1:1 Langmuir model for binding (red lines). Mean KD values obtained from 3
experiments are reported. (e) ScpA activity against rhC5a in the presence of 10, 150
and 1000 mM NaCl (lanes 2 to 4). Uncleaved rhC5a (lane 1) is shown for
comparison. (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
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majority (88%) of the 10.2 kcal/mol of total binding energy (DG
bind, Table 1). The remaining 12% of the binding energy is attribu-
table to interactions with the 7 C-terminal tail residues presum-
ably in the substrate binding cleft. According to the published
model for C5a binding [44], the core portion of C5a is too large
to fit into the active site cleft. Thus, the high affinity binding of
rhC5acore along with the competitive binding data indicated that
the bulk of substrate interactions occur at a site outside of the ScpA
active site (i.e. an exosite).
3.5. R74 is the dominant residue contributing to the tail interaction.
To examine the contribution of the R74 residue to substrate
specificity the interaction of ScpAS512A with rhC5adR was examined
by SPR. ScpAS512A binds to rhC5adR with a KD of 191 nM (Table 1
and Fig. 3c), intermediate in value between the KDs for rhC5a and
rhC5acore. This 6-fold increase in KD relative to full length rhC5a
indicates that interactions with R74 contributes 1.0 kcal/mol to
binding. Thus, interactions with R74 provide the majority (83%)
of the 1.2 kcal/mol contributed by interactions with all
7 C-terminal residues.
3.6. The 7 C-terminal tail residues facilitate substrate binding.
The SPR experiments also provide rates of association and dis-
sociation for the studied interactions and thus allow further anal-
ysis of the substrate binding process. From Table 1, the ka for
rhC5a is 13.1 X 104 M1s1 while the ka values for rhC5adR and
rhC5acore are 6.17 X 104 M1 s1 and 3.52 X 104 M1 s1 respec-2361tively. The association rate for binding rhC5a is 2.1 times faster
than for rhC5adR and 3.7 times faster as compared to for rhC5acore.
Thus, the ka for binding decreases when the tail is either removed
or truncated, indicating that the presence of the C-terminal tail
residues accelerates the association of the substrate. This would
suggest that while most of the stabilizing interactions involve the
residues in the core of the substrate, the tail residues facilitate
the formation of these interactions possibly by aiding proper posi-
tioning of the substrate on ScpA. The tail residue interactions in the
prime side of the active site are expected to involve the PA domain
[44]. Thus, these observations highlight the possibility that interac-
tions between the tail residues and the PA domain facilitate com-
munication between the active site and exosite.3.7. Binding and cleavage of rhC5a to ScpA is dependent on NaCl
concentration.
Based on amino-acid composition, ScpA and rhC5a are expected
to be oppositely charged at pH 7.4 (net charges of 31 and + 5 for
ScpA and rhC5a respectively). Thus, rhC5a binding was measured
in the presence of increasing NaCl concentrations. Comparison of
the sensorgrams for binding at 150 mM (Fig. 2a) versus 350, 550,
750 and 950 mM (Fig. 4a-4d) clearly show the salt dependence
of ScpA-rhC5a interaction. The KD increased from 34 to 466 nM
as buffer NaCl concentrations increased from 150 to 950 mM
(Table 1). This decrease in substrate binding affinity is due mainly
to a 6.7-fold lower ka (13.1 X 104 to 1.953 X 104 M1s1), as com-
pared to an ~ 2-fold increase in kd (4.4 X 10-3 to 9.10 X 10-3 s1).
The impact of increased ionic strength on ka supports the contribu-
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2362tion of electrostatic interactions during the association of the
substrate.
In these binding experiments, it is possible that the high con-
centrations of NaCl may have impacted on the fold of ScpA or pos-
sibly the substrate. We therefore evaluated the activity of the
active form of ScpA at higher concentrations of NaCl. Interestingly,
the simple gel assays show that ScpA not only retains its activity at
1 M NaCl, but in fact cleaves the substrate more efficiently at the
higher salt concentration (Fig. 4e). This would not be expected
given that substrate affinity decreases with higher salt. The activity
assays were conducted with high substrate concentrations
(18 mM), possibly well above the Km for rhC5a at 1 M NaCl, thus
the enhanced activity may be related to a higher Vmax or turnover
rate under these conditions.
3.8. Arginine residues, but not lysine residues in the core of C5a
contribute to binding
The binding studies in the presence of higher salt concentra-
tions indicated that association of the substrate involved ionic
interactions (Section 3.7). Substrate binding was also shown to
be dominated by interactions with rhC5acore (Section 3.4), thus
the contribution of positively charged core residues was examined
by SPR. A panel of single and double mutants of rhC5a were gener-
ated using the publishedmodel of the ScpA-C5a complex as a guide
(Fig. 5a and 5b show stereo representations of the ScpA-complex
and C5a, respectively). ScpA activity was demonstrated against
all mutants (Supplemental Fig. S2) supporting proper folding of
the substrate.
Mutations in 3 of the 4 total R residues in the C5a core (R37A,
R40A and R46A) were observed to decrease binding affinity rela-
tive to rhC5a (Table 1). These residues occur in the region encom-
passing C5a helix III and the loop linking helix III and helix IV
(Fig. 5b). The observed KDs for rhC5aR37A, rhC5aR40A and the
rhC5aR46A are 217 nM, 234 nM and 162 nM, respectively (Fig. 5e-
g), each mutant decreasing the binding energy by approximatelyig. 5. Model of the ScpA-hC5a complex. (a) The stereo diagram shows the ScpA-
5a complex with hC5a (cartoon diagram) on the surface of ScpA. The coordinates
r the model are from the docking analysis described in Kagawa et al. [44]. ScpA is
olored by domains, with the catalytic domain (‘CAT’) domain in salmon, the PA
omain in blue, and the Fn1–Fn3 domains in green, cyan, and yellow, respectively.
C5a is shown as a cartoon model with the core portion (PN, orange) on the ScpA
n2 domain and tail residues (PC, purple) extended through the prime side of the
ctive site. The location of the scissile bond is indicated with a red arrow. Sidechains
f hC5a arginine residues found to impact on binding are shown with space filling
odels and labelled ‘a’ (R37), ‘b’ (R40), ‘c’ (R46), and ‘d’ (R74). Panel (b) shows a
tereo diagram the hC5a model indicating locations of all residues mutated in this
tudy (shown as stick models). hC5a is colored as in panel A. The four hC5a helices
re labelled ‘I’ to ‘IV’. The location of the C27 sidechain is indicated with an asterisk.
anels (c) to (h) show representative sensorgrams of ScpAS512A binding to
hC5aK4A,K5A, rhC5aK12A,K14A, rhC5aR37A, rhC5aR40A, rhC5aR46A, and rhC5aK49A respec-
ively. Observed data (black lines) are plotted with curves obtained from global
tting of data with a 1:1 Langmuir model for binding (red lines). Mean KD values
btained from 3 experiments are reported. Panel (i) shows a reaction scheme where
inding of full-length hC5a (‘S’) occurs with a conformational change in ScpA (‘E’ to
’). The C-terminal ‘tail’ residues (‘PC’) are released during the acylation step.
eacylation produces a complex (‘F∙PN’) between the enzyme and core portion of
C5a (‘PN’). Dissociation of PN is faster from ‘F’ and thus not rate limiting in the
atalytic cycle. Binding of the ‘PN’ product to the ‘E’ ScpA state is accompanied by a
low rate of dissociation as measured in SPR studies. (For interpretation of the
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predominantly due to a faster dissociation rates for binding rather
than slowing the rate of association. The kd for rhC5aR37A
(17.6  10-3 s1), rhC5aR40A (20.5  10-3 s1) and rhC5aR46A
(17.8  10-3 s1) mutants increased by 4.0, 4.7 and 4.0-fold, respec-
tively, in comparison to rhC5a interaction (4.4 10-3 s1). This sug-
gests that these residues mainly contribute short range
interactions in the bound state rather than facilitating formation
of the complex. Of the 3 tested arginine residues in the core, R37
and R40 make the largest contribution to binding impacting both
ka and kd indicating their roles in the formation as well as the sta-
bility of the bound state.
Five of the 7 total lysine residues in the C5a core were also
mutated to examine their role in binding (Fig. 5b). 4 of the 5 residues
(K4, K5, K12 andK14) are in helix I and intera-helical loop 1, outside
the 3 central disulfide bridged helices (helices II-IV). The fifth lysine
residue (K49) is in helix IV. These mutations did not affect binding
affinity as significantly as mutations of the arginine residues.
The observed KDs range between 25.6 and 32.5 nM (Fig. 5c, 5d,
5 h and Table 1). Interestingly, the association rates for all lysine
mutants (15.8 – 19.5 X 104 M1s1), are marginally faster than
for rhC5a (13.1 X 104 M1s1), while the dissociation rates are rel-
atively unchanged. This shows that in contrast to R37, R40 and
R46, these lysine residues do not contribute significantly to the sta-
bility of the enzyme-substrate complex.
In summary, positively charged residues important for binding
identified in these studies are located on one side of the C5a mole-
cule in the region spanning Helix III, Helix IV and the intervening
loop.
4. Discussion
The importance of complement in human inflammatory dis-
eases is well established. However, in recent months there is
increased awareness of the impact of complement activation in
disease because of its role in the progress and severity of COVID-
19 infections. A recent study reported that C5a levels in COVID-
19 patients correlated with disease severity [2,24]. Several groups
are targeting C5a or its biological receptor C5aR1 using monoclonal
antibodies (MAbs) to C5, C5a and C5aR1. These studies are showing
promise in late-stage clinical trials [3–5]. The potential of using an
enzyme to target C5a has yet to be explored.
Of particular interest is the use of bacterial proteases which nat-
urally target components of the human immune system and mod-
ulate the immune response, a type of immunomodulatory enzyme
(IME). The potential of exploitation of IMEs is exemplified by the
streptococcal proteases IdeS and ScpA. The former targets IgG
and is being developed as a candidate therapeutic in clinical trials
[37], while the latter targets C5a and has been proposed as a means
for targeting the inflammatory response in sepsis [9]. Intervention
with therapeutic proteases has clear advantages of use of MAbs.
While both types of biologic can be highly specific, the action of
enzymes is catalytic in nature as opposed to stoichiometric for
MAbs. Thus, the required therapeutic dose of IMEs could be signif-
icantly lower in comparison to MAbs. Minimizing the amount of
biologic administered to the patient would reduce associated risks
of side-effects, and the ultimate cost of the therapy. To better
develop ScpA as a potential therapeutic resource, a more complete
understanding of the enzyme is essential. This includes character-
istics such as mechanical and chemical stability, engineering to
remove functions such as fibronectin binding [38], as well as
how the specificity of the enzyme is affected by different environ-
mental conditions. Thus, the first objective of these studies was to
obtain sensitive tools to benchmark the activity of ScpA and the
interaction with its substrate hC5a.2363Enzyme kinetic characterization utilizing a substrate based on
the full length hC5a shows that ScpA cleaves C5a with a Km of
185 nM and the kcat a 0.886 s1 (Section 3.2). In comparison,
Anderson and co-workers reported a Km of 360 mM and a kcat of
1.1 s1 using 16 residue peptide which lacks the bulky N-
terminal core portion of C5a [19]. The >1000-fold lower Km,
reported herein, indicates that significant interactions with C5a
occur outside the active site thus supporting the importance of
exosite interactions in substrate recognition. Significantly, a Km
in the low nM range agrees well with the physiological concentra-
tions of C5a (12 nM) reported in intra-abdominal infection [22].
The analyses also showed that ScpA is a relatively slow enzyme,
with the kcat value falling at the lower end of reported values for
other multidomain subtilases. For example, reported values of kcat
for Furin can be more than 100 s1 for substrates with nM Kms
[40,40]. The low kcat for ScpA is potentially due to conformational
changes related to the enhanced specificity of the enzyme.
The mode of interaction between ScpA and C5a was also exam-
ined in SPR binding experiments (Section 3.3). A KD of 34 nM was
observed for binding between the ScpAS512A inactive mutant and
the substrate rhC5a. This is in good agreement with the K ITCD mea-
sured in ITC experiments for solution binding (30.8 nM). The ITC
data also showed that binding is enthalpically driven, consistent
with the large number of hydrogen bonds and salt-bridges pre-
dicted for the complex [44]. The observed binding affinity is much
lower than previously reported by Terao and co-workers [21] in
studies with the active enzyme (KD 7.25 mM). As with the enzyme
kinetic studies, the low nM range KD, reported herein, is in good
agreementwithwhat is known about C5a levels in vivo. The tools used
in these analyses allow probing of ScpA activity and substrate interac-
tions in amanner not previously possible. Themethods described here
are currently being applied to examine the selectivity of the enzyme
for C5a and C3a from different species which will inform interpreta-
tion of animal studies on S. pyogenes virulence as well as model selec-
tion for preclinical evaluation of an ScpA therapeutic.
The SPR experiments (Sections 3.3 to 3.5, 3.7 and 3.8) with the
full length rhC5a and truncated forms of rhC5a (rhC5acore and
rhC5adR) support 4 general features of the proposed model for sub-
strate binding by ScpA [44]. First, rhC5a binding by ScpA is domi-
nated by interactions between the core portion of rhC5a and an
exosite, which we propose to be located on the Fn2 domain due
to its proximity to the entrance of the active site. Participation of
an exosite is indicated by the nM binding affinity of rhC5acore (KD
240 nM) accounting for 88% of the substrate binding energy (DG
bind). Residues of the rhC5acore form an a-helical bundle, reported
to be too bulky to access the ScpA active site in docking studies
[44]. Second, interactions with the 7 C-ter C5a tail residues make
a smaller contribution to substrate binding affinity. Observed bind-
ing affinities for rhC5acore and rhC5adR show that interactions with
the seven C5a tail residues (68–74) contribute 12% or 1.2 kcal/mol
of DGbind of which 83% or 1 kcal/mol involve hC5a residue R74.
The tail residues are the C-ter (PC) product released by ScpA and
thus expected to bind in the prime side of the active site in an
extended conformation with potential interactions involving resi-
dues of the catalytic and PA domains [44]. Interestingly, the pres-
ence of the tail residues was also shown to increase the rate of
association. Thus, interactions between the tail residues and the
PA domain may play a role in communicating events in the active
site to the exosite and/or participate in orienting the substrate dur-
ing binding. The third feature supported in these rhC5a binding
experiments is the participation of electrostatic interactions in
substrate binding. Point mutations, removing a subset of positively
charged side chains in the substrate, impacted on substrate bind-
ing. In addition, the binding affinity for rhC5a was observed to
decrease by nearly 14-fold as the concentration of NaCl increased
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of a 6.7-fold decrease in the ka. The slower association rates at
higher NaCl concentrations would be consistent with shielding of
longer-range interactions between the large lobes of oppositely
charged electrostatic potential located on the hC5a core and ScpA
Fn2 domain. Finally, these features are consistent with the pro-
posed two-step binding model where electrostatic recruitment of
the substrate to the ScpA surface, combines with conformational
changes in governing substrate specificity. This is supported by
the magnitude of ka for rhC5a, which is in a range consistent with
protein interactions that are governed neither by diffusion nor by
slower large-scale conformational changes [36].
The SPR studies also examined binding to a panel of hC5a
mutants to gain additional insight into ScpA substrate specificity.
Alanine mutants of 8 positively charged K and R residues were
tested since ScpA and hC5a are oppositely charged at neutral pH
and substrate binding affinity was observed to be salt dependent
(Section 3.7). Mutation of 3 R residues in Helix III (R37), Helix IV
(R46) and in the Helix III-IV loop (R40), which are in the cross-
linked C5a core, each decreased binding affinity by approximately
1 kcal/mol. The impact of these mutations on substrate binding
affinity provides additional evidence that exosite interactions play
a significant role in hC5a binding. Interactions with these residues
would involve residues outside of the ScpA active site since they
are located more than 20 Å from the scissile bond. In contrast,
mutation of the 5 K residues (Fig. 5c, 5d and 5h) in Helix I (K4,
K5 and K12), Helix IV (K49) and in the Helix I-II loop of C5a
(K14) had little effect on the binding affinity. These residues do
not form specific interactions with ScpA since the mutations did
not significantly alter the kd of binding. The expectation based on
the high salt binding studies was that mutations of lysine or argi-
nine residues would identify residues involved in long range elec-
trostatic interactions. However, no single mutation accounts for
the observed decrease in ka at high salt. It is possible that the
long-range effect involves other untested charged residues and/or
is a cumulative effect over multiple residues.
While the data presented here support the general features of
the model of the ScpA-C5a complex proposed [44], discrepancies
between the kinetic parameters obtained from the enzymatic
and SPR analyses may indicate additional complexity in the ScpA
catalytic cycle. It is often assumed that proteases follow the 3-
step mechanism for substrate hydrolysis. This involves binding of
the substrate to form the Michaelis complex, followed by two
chemical transformation steps (acylation and deacylation). The
rate of dissociation for the second product (PN) is typically thought
to be fast relative to the rate of deacylation and thus not explicitly
included in the expressions for kcat or Km. For ScpA, dissociation of
the core portion (PN) measured by SPR is very slow (kd 8.5 X 10-3
sec-1 for rhC5acore) and would be rate limiting for a subtilase [39].
However, the rate of substrate hydrolysis by ScpA is clearly not
limited by the PN dissociation rate measured by SPR with a more
than 100-fold faster kcat (0.886 sec-1). The inconsistencies in these
values may indicate that efficient progression through the catalytic
cycle involves ScpA conformational state(s) that require appropri-
ate interactions with both core and tail residues in an intact full-
length substrate. This is illustrated in Fig. 5i where an ScpA confor-
mational state ‘F’ is adopted in the ES complex upon binding of the
full length hC5a. Release of the core in the catalytic cycle would
occur from a conformational state accessed only in the presence
of the tail. Dissociation of the PN from this state may be faster than
indicated by SPR studies, and thus not rate limiting. In the absence
of the tail residues, the core binds to ScpA with a slow dissociation
rate potentially forming an inhibited enzyme complex. This sce-
nario implies that recognition of both parts of substrate are critical
for a productive encounter with the enzyme and may be an impor-
tant feature in the specificity of ScpA and similar enzymes.2364The emerging view of ScpA and related subtilases is that selec-
tion of their substrates is a dynamic two-step process involving
flexibility in the domains around the active site and in the C-ter
of the substrate. Structural and molecular dynamics studies indi-
cate that the PA domains in ScpA and the related IL-8 cleaving sub-
tilisin SpyCEP are capable of adopting different orientations [41]. In
mutagenesis studies, Bruinenberg et al. demonstrated that deletion
of the PA domain in the CEP from Lactococcus lactis modified the
caseinolytic specificity but not the activity of the enzyme [42]. As
suggested for SpyCEP recognition of the N-terminal ELR motif in
IL-8, mobility of the PA domain in ScpA could allow crucial interac-
tions with the N-terminal core portion of the C5a as well as with
the Fn2 domain and thus either open or modify features in the
prime side of the active site. In this manner, PA domain sensing
of appropriate contacts at the exosite would be an additional
mechanism for ensuring proper substrate selection. Additional
studies with ScpAmutants are required to unequivocally show that
residues distant from the active site, for example in the Fn2
domain, are important for substrate binding and specificity. Using
the tools developed herein, it is possible to evaluate these muta-
tions systematically. Furthermore, it is possible to test the suscep-
tibility of C5a from different species to the action of ScpA, which
will contribute to a better evaluation of pre-clinical animal models.5. Concluding remarks
The enzymatic and binding studies presented here provide the
first detailed information on the activity and specificity of the
C5a peptidase ScpA. Bioinformatic analysis identified many CEPs
in Gram positive organisms that inhabit the human gut [43] which
may participate in modulating the host immune response in a
manner similar to ScpA. This makes ScpA the prototype of an
expanding group of immuno-modulatory enzymes (IMEs) with
potential medical and biotechnological applications. The use of
IMEs as a strategy for therapeutic intervention has clear advan-
tages over use of MAbs. Both can be highly specific, but the cat-
alytic nature of enzymes means that the dose of therapeutic
required for treatment would be significantly lower for an enzyme.
Minimizing the amount of biologic administered to the patient
reduces associated risks of side-effects, and the ultimate cost of
the therapy. Engineering of IMEs, such as ScpA, for exploitation
as anti-complement or anti-cytokine therapies will require
detailed analyses, such as those reported here, to establish sub-
strate preference or hierarchy of activity against these important
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